The Global next generation sequencing market in terms of revenue was estimated to be worth $13 billion in 2022 and is poised to reach $27 billion by 2030, growing at a CAGR of 15.7% from 2022 to 2030. The increasing demand for personalized medicine, rising prevalence of cancer and genetic disorders, and decreasing costs of sequencing are some of the key factors driving the growth of the market. The global next generation sequencing (NGS) market refers to the market for technologies and services used to perform high-throughput DNA sequencing. NGS technologies have revolutionized genomics research and are being used in a wide range of applications including clinical diagnosis, drug discovery, and agriculture.

Browse 215 market data Tables and 96 Figures spread through 312 Pages and in-depth TOC on "Next Generation Sequencing Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/next-generation-sequencing-market-248705/

The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and genetic disorders is driving the demand for NGS-based diagnostic and treatment solutions. The development of new sequencing technologies and platforms with higher accuracy, speed, and throughput is fueling the adoption of NGS in research and clinical applications.

Market Dynamics

Despite the decreasing cost of sequencing, the cost of NGS equipment and services remains relatively high, which may limit adoption by some researchers and clinicians. The lack of standardization in NGS workflows, data analysis, and interpretation may limit the reproducibility and comparability of results across different laboratories and platforms.

Maintaining high-quality data is critical for the accuracy and reproducibility of NGS results. However, quality control can be challenging due to the complexity and variability of NGS workflows and the large amount of data generated. The analysis and interpretation of NGS data can be complex and require advanced bioinformatics skills. The development of new bioinformatics tools and workflows is needed to simplify data analysis and make it more accessible to a wider range of researchers and clinicians.

The growing adoption of NGS in research and clinical applications presents an opportunity for the development of new applications and solutions in areas such as oncology, infectious diseases, and precision medicine. The expansion of NGS into emerging markets such as Asia-Pacific and Latin America presents an opportunity for growth and market penetration. The development of cost-effective solutions and the localization of services and support are important for success in these markets.

Single-molecule real-time sequencing is a newer technology in the NGS market, driven by its ability to provide long-read sequencing data with high accuracy and throughput. It is commonly used in applications such as genome assembly, haplotype phasing, and epigenetic analysis. The "others" category includes emerging sequencing technologies such as nanopore sequencing, hybridization-based sequencing, and synthetic long-read sequencing. These technologies present significant opportunities for growth and innovation in the NGS market, driven by their ability to provide long-read sequencing data with high accuracy and throughput.

Services are the fastest-growing product segment in the NGS market, driven by the increasing demand for NGS-based services such as sequencing, data analysis, and bioinformatics. The services segment is further sub-segmented into sequencing services, data analysis services, and other services such as consulting and training.

The consumables segment is expected to continue to dominate the NGS market, driven by the increasing demand for reagents, kits, and other consumables in NGS-based research and clinical applications. The platforms segment is also expected to grow, driven by the increasing adoption of NGS platforms in research and clinical applications. The services segment presents significant opportunities for growth, driven by the increasing demand for NGS-based services such as sequencing, data analysis, and bioinformatics.

Regional Analysis

The market is segmented based on product & service, technology, application, end use, and region. Based on product & service, the market is divided into consumables, platforms, and services. The consumables segment is expected to account for the largest share of the market due to the high usage of reagents, kits, and other consumables in NGS workflows.

Latin America presents significant opportunities for growth and market penetration, driven by the increasing adoption of NGS in research and clinical applications. Brazil, Mexico, and Argentina are the largest markets in the region, accounting for a significant share of the global market.

The Middle East and Africa present significant opportunities for growth and market penetration, driven by the increasing demand for genomics research and personalized medicine. Saudi Arabia, South Africa, and the United Arab Emirates are the largest markets in the region, accounting for a significant share of the global market.

Competitive Analysis

Illumina is a leading player in the NGS market, offering a wide range of sequencing platforms, consumables, and services for research and clinical applications. The company has a dominant market share in the NGS market, driven by its established track record of accuracy, throughput, and affordability.

Thermo Fisher Scientific is another major player in the NGS market, offering a comprehensive portfolio of sequencing platforms, consumables, and services for research and clinical applications. The company has a strong market presence in the NGS market, driven by its focus on innovation and customer-centric approach.

In 2020, Illumina Inc. announced its intention to acquire Grail Inc., a cancer detection startup, for $8 billion. The acquisition would strengthen Illumina's position in the NGS market by adding Grail's innovative cancer detection technology to its portfolio.

In 2020, BGI Genomics Co. Ltd., a subsidiary of BGI Group, raised $207 million in a public offering on the Shenzhen Stock Exchange. The funds raised would be used to expand the company's NGS sequencing capacity and develop new applications for its sequencing technology.

In 2019, Qiagen N.V. acquired N-of-One, Inc., a provider of molecular decision support solutions, for $248 million. The acquisition would strengthen Qiagen's portfolio of bioinformatics solutions for NGS data analysis.

In 2019, Pacific Biosciences of California, Inc. raised $100 million in a public offering of common stock. The funds raised would be used to support the development and commercialization of the company's long-read sequencing technology.

In 2018, Illumina Inc. acquired Edico Genome, a provider of data analysis solutions for NGS, for $100 million. The acquisition would enable Illumina to integrate Edico's data analysis technology into its sequencing platforms, improving the speed and accuracy of NGS data analysis.

Segmentation Analysis of The Global Patient Engagement Solutions Market 2016-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzes the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global next sequencing market report based on capacity, vehicle, application, and propulsion type along with regional analysis. 

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• WGS
• Whole Exome Sequencing

Targeted Sequencing & Resequencing

• DNA-based
• RNA-based

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Platforms
• Sequencing
• Data Analysis
• Consumables
• Sample preparation
• Target Enrichment
• Others

Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology
• Diagnostics and Screening
• Oncology Screening
• Sporadic Cancer
• Inherited Cancer
• Companion Diagnostics
• Other Diagnostics

Research Studies

• Clinical Investigation
• Infectious Diseases
• Inherited Diseases
• Idiopathic Diseases
• Non-communicable/Other Diseases

Reproductive Health

• NIPT
• Aneuploidy
• Microdeletions
• PGT
• Newborn Genetic Screening
• Single Gene Analysis
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics

Workflow Outlook (Revenue, USD Million, 2018 - 2030)

Pre-sequencing

• NGS Library Preparation Kits
• Semi-automated Library Preparation
• Automated Library Preparation
• Clonal Amplification

Sequencing

• NGS Data Analysis
• NGS Primary Data Analysis
• NGS Secondary Data Analysis
• NGS Tertiary Data Analysis

Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America